The main aim of this clinical trial is to assess the safety of PD5K3 in patients aged 18 to 65 years. The main questions it aims to answer are:
* Is PD5K3 safe in adult? Researchers will compare PD5K3 to an active comparator pegaspargase to see if PD5K3 is safe and active in human.
Participants will
* Receive a single dose injection of PD5K3, pegaspargase or placebo according to weight,
* Visit the clinic for assessment.